Extracorporeal Pulse Activation Technology (EPATĀ®)
EPATĀ® is an innovative, FDA approved, non-invasive way to treat pain, fascia disorders and joint issues. It is based on a unique set of pressure waves that stimulate the metabolism, breaks up scar tissue, enhances blood circulation and stem cell activity; accelerating the healing process. Damaged tissue gradually regenerates and eventually heals. The biggest benefit is pain relief. Over 90% of EPAT patients report significantly reduced or eliminated pain. Effective against tendonitis pain (golfer/tennis elbow, plantar fasciitis, QL/Sciatic pain), frozen shoulder, fascia disorders, muscular pain and tightness, trigger point release and chronic joint issues.
What disorders can be treated?
Generally, acute or chronic musculoskeletal pain and/or pain that significantly impairs mobility or quality of life. Areas include:
- Neck
- Shoulder
- Back and spine
- Upper extremity
- Lower extremity
- Foot and ankle
- Myofascial trigger point
What are the expected results
The beneficial effects of Extracorporeal Pulse Activation Technology (EPATĀ®) are often experienced after only 3 treatments. Some patients report immediate pain relief after the treatment, although it can take up to 4 weeks for pain relief to begin.
The procedure focuses on eliminating pain and restoring mobility, thus improving your quality of life.
Is it safe?
Yes. This FDA cleared technology was developed in Europe and is currently used around the globe. A wealth of medical experience, state-of-the-art engineering, and optimal quality have been built into each EPATĀ® device; and extensive clinical studies and tests have confirmed its safety and efficacy. When performed by a qualified caregiver, Extracorporeal Pulse Activation Technology (EPATĀ®) has virtually no risks or side effects.
Actual Patient Results
ESWT was able to stimulate the proliferation of fibroblast and keratocyte cells leading to higher number, density and realignment of collagen fibers Type I, increase of expression of FGF1, FGF2 and FGFR1 indicating the neocollagenesis and neoelastogenesis and the expression of Ki67 for the proliferation of endothelial cells of the skin in individual with obesity. ESWT was associated with a significant increase of cell proliferation and collagen expression in flaccid skin of individuals who achieved weight loss before bariatric surgery, leading to promising results for the repair and prevention treatment of skin flaccidity in patients with obesity.
